Related Experiment Video
Updated: Jan 28, 2026

De Novo Generation of Somatic Stem Cells by YAP/TAZ
Published on: May 7, 2018
SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma
Ilka Isfort1,2, Magdalene Cyra1,2, Sandra Elges2
1Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
Synovial sarcoma is driven by SS18-SSX, which activates YAP/TAZ signaling. Targeting this pathway with verteporfin inhibits tumor growth, offering a new therapeutic strategy for this soft tissue malignancy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Synovial sarcoma is a soft tissue malignancy driven by the SS18-SSX fusion protein.
- The precise signaling pathways regulated by SS18-SSX remain incompletely understood, hindering targeted therapy development.
Purpose of the Study:
- To investigate the role of the Hippo signaling pathway effectors YAP/TAZ in synovial sarcoma pathogenesis.
- To explore the therapeutic potential of targeting YAP/TAZ signaling in synovial sarcoma.
Main Methods:
- Immunohistochemical analysis of YAP/TAZ in synovial sarcoma tissues.
- In vitro studies using synovial sarcoma cell lines and mesenchymal stem cells to assess SS18-SSX dependency and YAP/TAZ function.
- RNAi-mediated knockdown and small-molecule inhibitor (verteporfin) treatment to modulate YAP/TAZ-TEAD activity.
- In vivo validation in avian chorioallantoic membrane and xenograft models.
Main Results:
- Nuclear YAP/TAZ and downstream targets (FOXM1, PLK1) were detected in a significant subset of synovial sarcomas.
- SS18-SSX knockdown reduced YAP/TAZ-TEAD activity, while SS18-SSX overexpression induced aberrant YAP/TAZ signaling via an IGF-II/IGF-IR loop.
- Verteporfin treatment and RNAi-mediated modulation of YAP/TAZ-TEAD significantly inhibited tumor cell growth in vitro and in vivo.
Conclusions:
- SS18-SSX drives YAP/TAZ signaling, playing a critical role in synovial sarcoma development.
- This study elucidates a key oncogenic signaling network in synovial sarcoma.
- Targeting SS18-SSX-driven YAP/TAZ pathways represents a promising therapeutic strategy for synovial sarcoma.
Related Concept Videos
Contact-dependent Signaling
Gap Junctions
In animal cells, gap junctions are formed...
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Structural Joints: Synovial Joints
Development of the Limb Synovial Joints
The mesenchymal stem cells differentiate into chondrocytes that form the hyaline cartilage, and later the cartilaginous model of the bone. This model further transforms into a bone. This process is known as endochondral ossification.
During development, the limbs...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

